Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1993-7-22
|
pubmed:abstractText |
Lysis of group A and B erythrocytes by human complement was studied by an anti-A (BRIC.131) and an anti-B (BRIC.30) IgM monoclonal antibody in a 51Cr-release assay. The relative concentration of membrane-bound immunoglobulins was detected by flow cytometric analysis, and the amount of C1q and C3 bound to the sensitized red cells was measured by using purified, 125I-labelled molecules. The direct haemolysis was identical with both reagents in the presence of excess and suboptimal complement over a wide range of antibody concentration (between 50 and 7000 ng/ml). The indirect effect of membrane-bound antibody, i.e. its influence on complement binding by sensitized bystander cells, was examined in a cold target competition assay in which sensitized, non-labelled cells are present when complement is incubated with sensitized labelled cells. We have found that the competitive capacity of sensitized erythrocytes correlated with the amount of membrane-bound immunoglobulins. In accordance with our earlier findings, an equal level of target and competitor cell lysis was obtained only if the fluid phase anti-B antibody concentration was 2 to 4 times higher than that of the anti-A antibodies. We demonstrate in this paper that the different competitive activity of IgM anti-A and anti-B monoclonal antibodies might be accounted for by differences in their C1q and C3 binding capacities.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/ABO Blood-Group System,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Complement C1q,
http://linkedlifedata.com/resource/pubmed/chemical/Complement C3,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin M
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0165-2478
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
35
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
213-7
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8514332-ABO Blood-Group System,
pubmed-meshheading:8514332-Antibodies, Monoclonal,
pubmed-meshheading:8514332-Binding, Competitive,
pubmed-meshheading:8514332-Complement Activation,
pubmed-meshheading:8514332-Complement C1q,
pubmed-meshheading:8514332-Complement C3,
pubmed-meshheading:8514332-Complement Hemolytic Activity Assay,
pubmed-meshheading:8514332-Erythrocyte Membrane,
pubmed-meshheading:8514332-Flow Cytometry,
pubmed-meshheading:8514332-Humans,
pubmed-meshheading:8514332-Immunoglobulin M
|
pubmed:year |
1993
|
pubmed:articleTitle |
Red-cell bound anti-A is more efficient than anti-B in competition for fluid phase complement.
|
pubmed:affiliation |
Department of Immunology, National Institute of Oncology, Budapest, Hungary.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|